Filter
17
Filtered Results: 17
Text search:
EMTCT
Global
Validation
Advisory
Committee,
Global
HIV,
Hepatitis
and
Sexually
Transmitted
Infections
Programmes
Featured
New Publications
5
Language
Document type
No document type
8
Guidelines
5
Studies & Reports
3
Strategic & Response Plan
1
Countries / Regions
Global
3
Asia
3
Nigeria
2
Ghana
1
Latin America and the Carribbean
1
South–East Asia Region
1
Namibia
1
Zambia
1
Authors & Publishers
Publication Years
Category
Countries
5
Clinical Guidelines
3
Toolboxes
HIV
9
NTDs
2
Validation of elimination of mother-to-child transmission, or vertical transmission, of HIV, syphilis and hepatitis B virus (HBV), is an attestation that a country has successfully met standard criteria for elimination, or for being at 1 of the 3 levels of achievement on the ‘Path to Elimination...
An overview of validation structures and responsibilities at national, regional and global levels.
This governance document supplements the global guidance document. Validation of elimination requires rigorous assessment at the national, regional and global levels of the impact and process indicato...
Guidance
Second Edition
Monitoring and Evaluation
Building on the 2021 Interim guidance, this second version and update, incorporates the lessons and feedback from the hepatitis pilots that successfully demonstrated the feasibility of measuring hepatitis B and C impact targets to demonstrate elimination, whilst highlighting challenges caused by hig...
Meeting Report
27–30 June 2017 Manila, Philippines
Meeting Report
Bangkok, Thailand 8-11 August 2016
Biennial Report. SUBMITTED TO THE UNITED NATIONS GENERAL ASSEMBLY SPECIAL SESSION ON HIV AND AIDS
Reporting period: January 2012 – December 2013
The objective of this concept note and the framework it outlines is the elimination of a group of CDs and the negative health effects they generate, which together create a tangible burden on affected individuals, their families and communities, and on health care systems throughout the Region. Thou...
These guidelines provide evidence-based guidance on the use of peripartum antiviral prophylaxis in HBsAg-positive pregnant women for the prevention of mother-to-child transmission of HBV.
